1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Biosimilars: Global Markets

Biosimilars: Global Markets

  • March 2018
  • 340 pages
  • ID: 919318
  • Format: PDF


Table of Contents

Report Scope:
Biosimilars are replicas of the innovator biopharmaceuticals.They offer the advantage of being less expensive as compared to their expensive counterparts.

The structural and manufacturing complexities associated with their development have led to extensive approval guidelines and regulations by the federal agencies.This report examines the biosimilar drugs in detail and provides an updated overview including its applications in various arenas of disease sectors.

The importance of analytical technologies in the biosimilar manufacturing led BCC Research to focus specifically on the current and emerging trends in biosimilar manufacturing and analytical testing.

The scope of the study is global.BCC analyzes each market and its application, new products and advancements, market projections and market shares.

This study surveys each market in all the geographic regions including North America, Europe and Emerging markets. The Emerging market covers all major countries like India, China, South Korea, Taiwan, Australia, New Zealand, Canada, Latin America, much of Africa, etc.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the biosimilar drugs industry.The company profiles highlight the bosimilar pipelines of relevant companies.

Some of the major players of the market include Pfizer Inc., Sandoz International GmbH, Biocon Ltd., Dr Reddy’s Laboratories Ltd., Amgen Inc., Teva Pharmaceuticals Inc., Celltrion Inc., Samsung Bioepis, and others.

BCC Research analyzes the current market situation by critically discussing the strengths, weaknesses, threats, and opportunities for the global biosimilars market.The market projections and market shares are examined for each region and type.

The latest news articles including new products, acquisitions and collaborations in each market are also dealt with in sufficient detail.

The report has also dealt with biobetters, their approval mechanisms and importance in the industry. (Biobetters are described as new molecular entities that are related to existing biologics by target or action, but they are deliberately altered to improve disposition, safety, efficacy, or manufacturing attributes.)

Excluded from this report are the generics of small-molecule drugs, and the biologics per se.The different requirements for approval and bioequivalence between generics and biosimilars puts them in an entirely different regime.

The diagnostic methods for monitoring disease progression are also outside the scope of this report.

Report Includes:
- 80 data tables and 16 additional tables
- An overview of the global market for biosimilars
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- A look at biosimilar product classes in various regions worldwide, as well as the worldwide pipeline for biosimilars
- Detailed analysis of the emerging framework in regulated markets, as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, as well the guidelines developed by the - World Health Organization
- Technology trends and patent analyses
- Comprehensive company profiles of key players in the market, including Allergan Plc., Bioton S.A., Cinnagen, Emcure Pharmaceuticals Ltd., LG Life Sciences, Neuclone and Pfizer Inc.

Biosimilars, also known as “follow-on biologics,” “similar biologics,” “biogenerics,” etc. are the generic versions of the biologic drugs. They are important biotherapeutic drugs that are used for the treatment of several serious and debilitating diseases. Most of the innovator biologics are billion-dollar drugs and have a sizeable share of the biopharmaceuticals market. The high cost associated with the biologics has created a situation of limited access for millions of patients around the globe, in particular, the emerging countries. The patent expirations of the blockbuster drugs have led to a growing interest in the development of biosimilars. Biosimilars have the potential to allow wide and affordable access of the drugs due to their lower cost.

It has been noted by industry analysts that, compared to an originator biologic, a biosimilar takes 60% less time to reach the market, with development costs only 15% to 20% of those of the biologics. Their prices being 20% to 30% cheaper than the original drugs, the biosimilars offer increased opportunity for patients, healthcare providers, and manufacturing companies alike.

The cost-effectiveness of biosimilars, soon-to-market approval option, and the billions of dollars’ worth market of term-end innovator biologics is luring many small and big pharmaceutical companies to capitalize in this market.The biosimilar industry comprises of pharmaceutical companies that range from clinical-stage companies to small-pharma companies with limited capabilities, as well as bigger pharmaceutical giants with established markets.

Though the domestic markets are more flourished in the current situation, collaborations and partnerships proving as popular strategies to gain market share globally.

Europe has set an example for other countries by establishing a well-worked framework for the approval of biosimilars. The U.S., with the enactment if the Affordable Care Act in 2010, also entered this market in 2015. Emerging markets, including countries in Asia, Latin America, Russia, etc., have several biosimilar products in the market since the early 2000s. The products in these countries were, however, considered inferior in quality as these countries did not have any regulatory guidelines for biosimilar approvals. Lack of any patent regulation also favored these countries and allowed the market of biosimilars to flourish in the emerging markets. Governments of many countries have now adopted the biosimilar guidelines, encouraging the growth of global biosimilars market. Although, the acceptance of biosimilar drugs has been slow in the U.S., the recent approvals by the Food and Drug Administration (FDA) amounting to eight approvals in 2016 and 2017 in contrast to a single approval in 2015, show that the trend towards biosimilars in the developed world is gaining traction.

The global biosimilars market is driven primarily by the blockbuster products and the related research pipeline.Currently, there is only a limited number of biosimilars in the market, restricted to the categories of growth hormones, growth factors, monoclonal antibodies, fusion proteins, interferons, and low-molecular-weight heparins (LMWHs).

During the examined period of this report, many more biosimilars, particularly in the categories of monoclonal antibodies indicated for the treatment of cancer, various autoimmune diseases, infectious diseases, and others are expected to be launched due to their impending patent expirations in the U.S. and Europe. There are at least 43 potential biosimilars candidates that are in late-stage clinical trials. The market of biosimilars is also encouraged by the successful joint ventures, collaborations and partnerships, and various licensing arrangements that are helping to boost the technical expertise, intellectual know-how, and market access for the partnering companies. An increase in the aging population, rising incidences of various diseases, and increasing pressure to cut healthcare expenditures are the growth drivers for the biosimilars market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
US Biosimilars Market , Dosage, Price & Clinical Pipeline Outlook 2025

US Biosimilars Market , Dosage, Price & Clinical Pipeline Outlook 2025

  • $ 2400
  • April 2019

"US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025" Report Highlights: US Biosimilar Market Current ScenarioUS Biosimilars Clinical Pipeline by Company, Indication & Phase: ...

Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • $ 2299
  • February 2019

The biosimilar market in Europe reached a value of US$ 2,934.6 Million in 2018. The market is further projected to reach a value of US$ 11,663.1 Million by 2024, growing at a CAGR of 24.9% during 2019-2024. ...

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

  • $ 2000
  • January 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on